Sage Journals: Discover world-class research

Abstract

Background:

Fingolimod is an oral drug approved for multiple sclerosis (MS) with an ability to trap central memory T cells in secondary lymphoid tissues; however, its variable effectiveness in individual patients indicates the need to evaluate its effects on other lymphoid cells.

Objective:

To clarify the effects of fingolimod on B-cell populations in patients with MS.

Methods:

We analysed blood samples from 9 fingolimod-treated and 19 control patients with MS by flow cytometry, to determine the frequencies and activation states of naive B cells, memory B cells, and plasmablasts.

Results:

The frequencies of each B-cell population in peripheral blood mononuclear cells (PBMC) were greatly reduced 2 weeks after starting fingolimod treatment. Detailed analysis revealed a significant reduction in activated memory B cells (CD38^int-high), particularly those expressing Ki-67, a marker of cell proliferation. Also, we noted an increased proportion of activated plasmablasts (CD138⁺) among whole plasmablasts, in the patients treated with fingolimod.

Conclusions:

The marked reduction of Ki-67⁺ memory B cells may be directly linked with the effectiveness of fingolimod in treating MS. In contrast, the relative resistance of CD138⁺ plasmablasts to fingolimod may be of relevance for understanding the differential effectiveness of fingolimod in individual patients.

Keywords

B cells CD38 CD138 fingolimod memory B cell multiple sclerosis plasmablast proliferation resistance sphingosine 1-phosphate receptor 1

Get full access to this article

View all access options for this article.

References

Kivisakk

Mahad

Callahan

. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann Neurol 2004; 55: 627–638.

Cyster

Schwab

. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Ann Rev Immunol 2012; 30: 69–94.

Cohen

Chun

. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759–777.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med 2010; 362: 387–401.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Mehling

Lindberg

Raulf

. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403–410.

Pilz

Harrer

Wipfler

. Tumefactive MS lesions under fingolimod: A case report and literature review. Neurology 2013; 81: 1654–1658.

Jander

Turowski

Kieseier

. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012; 18: 1650–1652.

Visser

Wattjes

Pouwels

. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79: 2000–2003.

10.

Leypoldt

Munchau

Moeller

. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: A case report. Neurology 2009; 72: 1022–1024.

11.

Izaki

Narukawa

Kubota

. [A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions, following fingolimod treatment]. Rinsho Shinkeigaku 2013; 53: 513–517.

12.

Min

Kim

Lee

. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18: 113–115.

13.

Baranzini

Jeong

Butunoi

. B-cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163: 5133–5144.

14.

Qin

Duquette

Zhang

. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102: 1045–1050.

15.

Hauser

Waubant

Arnold

. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

16.

Kowarik

Pellkofer

Cepok

. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011; 76: 1214–1221.

17.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

18.

Takahashi

Fujihara

Nakashima

. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006; 210: 307–313.

19.

Chihara

Aranami

Sato

. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701–3706.

20.

Gohda

Kunisawa

Miura

. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer’s patches for intestinal IgA responses. J Immunol 2008; 180: 5335–5343.

21.

Kabashima

Haynes

. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 2006; 203: 2683–2690.

22.

Corcione

Casazza

Ferretti

. Recapitulation of B-cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101: 11064–11069.

23.

Harp

Ireland

Davis

. Memory B cells from a subset of treatment-naive relapsing–remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010; 40: 2942–2956.

24.

Ruffin

Lantto

Pensieroso

. Immune activation and increased IL-21R expression are associated with the loss of memory B cells during HIV-1 infection. J Intern Med 2012; 272: 492–503.

25.

Gerdes

Lemke

Baisch

. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710–1715.

26.

Odendahl

Mei

Hoyer

. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005; 105: 1614–1621.

27.

Chihara

Aranami

Oki

. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One 2013; 8: e83036.

28.

Budde

L Schmouder

Nashan

. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transpl 2003; 3: 846–854.

29.

Vaessen

Van Besouw

Mol

. FTY720 treatment of kidney transplant patients: A differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol 2006; 15: 281–288.

30.

Mehling

Brinkmann

Antel

. FTY720 therapy exerts differential effects on T-cell subsets in multiple sclerosis. Neurology 2008; 71: 1261–1267.

31.

Johnson

Lapierre

Bar-Or

. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol 2010; 67: 1449–1455.

32.

Johnson

Evans

Durafourt

. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 2011; 187: 570–579.

33.

Nylander

Hafler

. Multiple sclerosis. J Clin Invest 2012; 122: 1180–1188.

34.

Meinl

Krumbholz

Hohlfeld

. B-lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 2006; 59: 880–892.

35.

Von Budingen

Bar-Or

Zamvil

. B cells in multiple sclerosis: Connecting the dots. Curr Opin Immunol 2011; 23: 713–720.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB

0.12 MB

0.21 MB

Differential effects of fingolimod on B-cell populations in multiple sclerosis